Cargando…
Newborn Screening Quality Assurance Program for CFTR Mutation Detection and Gene Sequencing to Identify Cystic Fibrosis
All newborn screening laboratories in the United States and many worldwide screen for cystic fibrosis. Most laboratories use a second-tier genotyping assay to identify a panel of mutations in the CF transmembrane regulator (CFTR) gene. Centers for Disease Control and Prevention’s Newborn Screening Q...
Autores principales: | Hendrix, Miyono M., Foster, Stephanie L., Cordovado, Suzanne K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332130/ https://www.ncbi.nlm.nih.gov/pubmed/28261631 http://dx.doi.org/10.1177/2326409816661358 |
Ejemplares similares
-
Assessing the Performance of Dried-Blood-Spot DNA Extraction Methods in Next Generation Sequencing
por: Hendrix, Miyono M., et al.
Publicado: (2020) -
The Role of Extended CFTR Gene Sequencing in Newborn Screening for Cystic Fibrosis
por: Bergougnoux, Anne, et al.
Publicado: (2020) -
Benign and Deleterious Cystic Fibrosis Transmembrane Conductance Regulator Mutations Identified by Sequencing in Positive Cystic Fibrosis Newborn Screen Children from California
por: Salinas, Danieli B., et al.
Publicado: (2016) -
Cystic Fibrosis-Screening Positive Inconclusive Diagnosis: Newborn Screening and Long-Term Follow-Up Permits to Early Identify Patients with CFTR-Related Disorders
por: Castaldo, Alice, et al.
Publicado: (2020) -
Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
por: Stefano, Daniela De, et al.
Publicado: (2014)